In fact, 29% of adults who are not currently using a GLP-1 say they would consider doing so if it were more accessible and cost-effective
If a patient fails to achieve desired results on tirzepatide monotherapy after adequate dose optimization, the appropriate next stepas supported by clinical guidelinesis to discontinue tirzepatide and switch to a different class of weight-loss medication (such as an orlistat or a future non-GLP-1 agent), not to add semaglutide
3 Saxenda (Liraglutida 18 mg) inyeccin subcutnea, solo con receta mdica, ayuda al control de peso crnico en adultos con obesidad o sobrepeso y una afeccin relacionada con el peso, como complemento a una dieta baja en caloras y ejercicio
Existing studies mostly focus on single pathways or cell types, lacking a comprehensive explanation of the systemic remodeling of immune-metabolic networks, especially the mechanisms of inter-organ metabolic-immune axes and metabolic crosstalk among different immune cell subsets remain unclear (Thenappan and Weir, 2024